Alignment Healthcare (NASDAQ:ALHC) COO Sebastian Burzacchi Sells 15,361 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) COO Sebastian Burzacchi sold 15,361 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total transaction of $274,040.24. Following the sale, the chief operating officer directly owned 258,630 shares in the company, valued at $4,613,959.20. The trade was a 5.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC opened at $18.16 on Friday. Alignment Healthcare, Inc. has a fifty-two week low of $11.63 and a fifty-two week high of $23.87. The company has a 50 day simple moving average of $20.51 and a two-hundred day simple moving average of $18.78. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -1,814.19, a P/E/G ratio of 2.66 and a beta of 1.18. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business earned ($0.16) earnings per share. The business’s revenue was up 44.4% on a year-over-year basis. Analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Analyst optimism — several brokerages have raised price targets and maintained Overweight/Buy views (Piper Sandler, KeyCorp, JPMorgan, Robert W. Baird), supporting upside expectations and a consensus “Moderate Buy” rating. MarketBeat ALHC Analyst Coverage
• Positive Sentiment: Recent earnings beat — Alignment reported Q4 revenue of ~$1.01B and EPS of ($0.05), topping consensus (revenue ~ $1.00B; EPS -$0.15), showing strong revenue growth (Y/Y +44%). This fundamental print remains supportive. Earnings Summary
• Neutral Sentiment: Zacks comparison piece — a valuation/comparison article contrasts ALHC with BrightSpring (BTSG); useful context for long-term investors but not an immediate market catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data appears erroneous (shows 0 shares / NaN changes). Do not treat published short-interest figures as evidence of rising short pressure until exchanges correct the data.
• Negative Sentiment: CEO sale — John E. Kao sold 73,046 shares at an average $17.84 (~$1.30M), trimming his stake ~3.93%. This large insider sale is a near-term negative signal for sentiment. SEC Filing — Kao
• Negative Sentiment: Multiple senior insider sales on Mar 18 — President Dawn C. Maroney (36,749 shares, $17.84; also several prior sales in March/Jan), COO Sebastian Burzacchi (15,361 shares, $17.84), Christopher J. Joyce (25,125 shares, $17.84), Hyong Kim (18,404 shares, $17.84), Andreas P. Wagner (12,000 @ $17.84 and 11,602 @ $18.22), and Robert L. Scavo (11,285 shares, $17.84). These clustered disposals by senior management create headline risk and downward pressure. Representative filings: Maroney — Maroney SEC Filing; Joyce — Joyce SEC Filing; Wagner filings — Wagner SEC Filing

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ALHC. JPMorgan Chase & Co. increased their target price on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. Robert W. Baird set a $28.00 price target on shares of Alignment Healthcare in a research note on Friday, January 30th. TD Cowen increased their price objective on shares of Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, UBS Group raised their price objective on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alignment Healthcare by 0.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after purchasing an additional 79,268 shares in the last quarter. Invesco Ltd. increased its holdings in Alignment Healthcare by 38.9% in the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after buying an additional 1,735,962 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in Alignment Healthcare by 6.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 15,452 shares of the company’s stock worth $305,000 after buying an additional 996 shares during the last quarter. Mackenzie Financial Corp raised its position in Alignment Healthcare by 25.6% in the 4th quarter. Mackenzie Financial Corp now owns 46,917 shares of the company’s stock worth $901,000 after buying an additional 9,552 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in Alignment Healthcare during the 4th quarter valued at about $396,000. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.